Paraoxonase 1 Activity in Patients with Chronic Obstructive Pulmonary Disease

References

• Somborac-Bačura A, Buljević S, Rumora L, Čulić O, Detel D, Pancirov D, Popović-Grle S, Varljen J, Čepelak I, Žanić-Grubišić T. Decreased soluble dipeptidyl peptidase IV activity as a potential serum biomarker for COPD. Clin Biochem 2012; 45:1245–1250.
   PubMed Web of Science ®Google Scholar
• Stanojkovic I, Kotur-Stevuljevic J, Milenkovic B, Spasic S, Vujic T, Stefanovic A, Llic A, Ivanisevic J. Pulmonary function, oxidative stress and inflammatory markers in severe COPD exacerbation. Respir Med 2011; 105:S31–37.
   PubMed Web of Science ®Google Scholar
• Isik B, Isik SR, Yolacan H, Isik MR. Serum malondialdehyde and paraoxonase levels in chronic obstructive pulmonary disease. Turk Respir J 2005; 6:19–21.
   Google Scholar
• Isik B, Isik RS, Ceylan A, Calik O. Trace elements and oxidative stress in chronic obstructive pulmonary disease. Saudi Med J 2005; 26:1882–1885.
   PubMed Web of Science ®Google Scholar
• Isik B, Ceylan A, Isik RM. Oxidative stress in smokers and non-smokers. Inhal Toxicol 2007; 19:767–769.
   PubMed Web of Science ®Google Scholar
• Tekes S, Isik B, Yildiz T, Simsek S, Isik RM, Bundak T. Chronic obstructive pulmonary disease and paraoxonase 1 192 and 55 gene polymorphisms. Biotechnol Biotechnol 2010; 24:1644–1647.
   Web of Science ®Google Scholar
• Rodrigo L, Hernádez AF, Lóez-Caballero JJ, Gil F, Pla A. Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact 2001; 137:123–37.
   PubMed Web of Science ®Google Scholar
• Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:78–88.
   PubMed Web of Science ®Google Scholar
• Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 2005; 38:153–163.
   PubMed Web of Science ®Google Scholar
• Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14:334–336.
   PubMed Web of Science ®Google Scholar
• Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000; 28:1335–1342.
   PubMed Web of Science ®Google Scholar
• Jakubowski H. Calcium–dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000; 275:3957–3962.
   PubMed Web of Science ®Google Scholar
• Teiber JF, Draganov DI, La Du BN. Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem Pharmacol 2003; 66:887–896.
   PubMed Web of Science ®Google Scholar
• Grdić Rajković M, Rumora L, Barišić K. The paraoxonase 1, 2 and 3 in humans. Biochemia Medica 2011; 21:122–130.
   Web of Science ®Google Scholar
• Naderi M, Hashemi M, Komijani-Bozchaloei F, Moazeni-Roodi A, Momenimoghaddam M. Serum paraoxonase and arylesterase activities in patients with pulmonary tuberculosis. Pathophysiology 2011; 18:117–120.
   PubMedGoogle Scholar
• Aviram M. Introduction to the serial review on paraoxonases, oxidative stress, and cardiovascular diseases. Free Radic Biol Med 2004; 37:1301–1303.
   PubMed Web of Science ®Google Scholar
• Su ND, Hung ND, Cheon–Ho P, Ree KM, Dai–Eun S. Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1). Biochim Biophys Acta 2009; 1790:155–160.
   PubMed Web of Science ®Google Scholar
• Yeung DT, Josse D, Nicholson JD, Khanal A, McAndrew CW, Bahnson BJ, Lenz DE, Cerasoli DM. Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase–like homology model. Biochim Biophys Acta 2004; 1702:67–77.
   PubMed Web of Science ®Google Scholar
• Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du B. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998; 18:1617–1624.
   PubMed Web of Science ®Google Scholar
• Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase–1. Clin Sci 2004; 107:435–447.
   PubMed Web of Science ®Google Scholar
• Durrington PN, Mackness B, Mackness MI. The hunt for nutritional and pharmacological modulators of paraoxonase. Arterioscler Thromb Vasc Biol 2002; 22:1248–1250.
   PubMed Web of Science ®Google Scholar
• Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005; 69:541–550.
   PubMed Web of Science ®Google Scholar
• Marchegiani F, Marra M, Olivieri F, Cardelli M, James RW, Boemi M, Franceschi C. Paraoxonase 1: genetics and activities during aging. Rejuven Res 2008; 11:113–127.
   PubMed Web of Science ®Google Scholar
• Mackness B, Durrington PN, Mackness MI. The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol 2002; 13:357–362.
   PubMed Web of Science ®Google Scholar
• Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important. Free Radic Biol Med 2004; 37:1317–1323.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Pulmonary Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: updated 2011. http://www.goldcopd.org (accessed Oct 15, 2012).
   Google Scholar
• Rajković MG, Rumora L, Juretić D, Grubisić TZ, Flegar-Mestrić Z, Vrkić N, Sinjeri Z, Barisić K. Effect of non-genetic factors on paraoxonase 1 activity in patients undergoing hemodialysis. Clin Biochem 2010; 43:1375–1380.
   PubMed Web of Science ®Google Scholar
• Landers JE, Shi L, Cho TJ, Glass JD, Shaw CE, Leigh PN, Diekstra F, Polak M, Rodriguez-Leyva I, Niemann S, Traynor BJ, McKenna-Yasek D, Sapp PC, Al-Chalabi A, Wills AM, Brown RH Jr. A common haplotype within the PON1 promoter region is associated with sporadic ALS. Amyotroph Lateral Scler 2008; 9:306–314.
   PubMed Web of Science ®Google Scholar
• Browne RO, Moyal-Segal LB, Zumsteg D, David Y, Kofman O, Berger A, Soreq H, Friedman A. Coding region paraoxonase polymorphisms dictate accentuated neuronal reactions in chronic, sub-threshold pesticide exposure. FASEB J 2006; 20:1733–1735.
   PubMed Web of Science ®Google Scholar
• Hu ML. Measurement of protein thiol groups and glutathione in plasma. Meth Enzymol 1994; 233:380–385.
   PubMed Web of Science ®Google Scholar
• Rahman I, Swarska E, Henry M, Stolk J, MacNee W. Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease? Thorax 2000; 55:189–193.
   PubMed Web of Science ®Google Scholar
• Torres-Ramos YD, Guzman-Grenfell AM, Montoya-Estrada A, Ramirez-Venegas A, Martinez RS, Flores-Trujillo F, Ochoa-Cautino L, Hicks JJ. RBC membrane damage and decreased band 3 phospho-tyrosine phosphatase activity are markers of COPD progression. Front Biosci (Elite Ed) 2010; 2:1385–1393.
   PubMedGoogle Scholar
• Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004; 37:1304–1316.
   PubMed Web of Science ®Google Scholar
• Litvinov D, Mahini H, Garelnabi M. Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci. 2012; 4:523–532.
   PubMedGoogle Scholar
• Barreiro E, Fermoselle C, MATEU-Jimenez M, S疣chez-Font, Pijuan L, Gea J, Curull V. Oxidative stress and inflammation in the normal airways and blood of patients with lung cancer and COPD. Free Radic Biol Med 2013; 65:859–871.
   PubMed Web of Science ®Google Scholar
• Cristóvão C, Cristóvão L, Nogueira F, Bicho M. Evaluaton of the oxidant and antioxidant balance in the pathogenesis of chronic obstructive pulmonary disease. Rev Porta Pneumol 2013; 19:70–75.
   PubMed Web of Science ®Google Scholar
• Van Eeden SF, Sin DD. Oxidative stress in chronic obstructive pulmonary disease: A lung systemic process. Can Respir J 2013; 20:27–29.
   PubMed Web of Science ®Google Scholar
• Pandey R, Singh M, Singhal U, Bihari Gupta K, Kumar Aggarwal S. Oxidative/Nitrosative stress and the pathobiology of chronic obstructive pulmonary disease. J Clin Diagn Res 2013; 7:580–588.
   Google Scholar
• James RW, Deakin SP. The importance of high–density lipoproteins for paraoxonase–1 secretion, stability, and activity. Free Radic Biol Med 2004; 37:1986–1994.
   PubMed Web of Science ®Google Scholar
• Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum paraoxonase/arylesterase's retained hydrophobic N–terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A–I stabilizes activity. Arterioscler Thromb Vasc Biol 1999; 19:2214–2225.
   PubMed Web of Science ®Google Scholar
• Nevin DN, Zambon A, Furlong CE, Richter RJ, Humbert R, Hokanson JE, Brunzell JD. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol 1996; 16:1243–1249.
   PubMed Web of Science ®Google Scholar
• Senti; M, Tomás M, Anglada R, Elosua R, Marrugat J, Covas MI, Fitó M. Interrelationship of smoking, paraoxonase activity, and leisure time physical activity: a population-based study. Eur J Intern Med 2003; 14:178–184.
   PubMedGoogle Scholar
• Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun 1997; 236:289–293.
   PubMed Web of Science ®Google Scholar
• Sepahvand F, Shafiei M, Ghaffari SM, Rahimi-Moghaddam P, Mahmoudian M. Paraoxonase phenotype distribution in a healthy Iranian population. Basic Clin Pharmacol Toxicol 2007; 101:104–107.
   PubMed Web of Science ®Google Scholar
• Rozenberg O, Aviram M. S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity. Biochem Biophys Res Commun 2006; 351:492–498.
   PubMed Web of Science ®Google Scholar
• Jaouad L, de Guise C, Berrougui H, Cloutier M, Isabelle M, Fulop T, Payette H, Khalil A. Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups. Atherosclerosis 2006; 185:191–200.
   PubMed Web of Science ®Google Scholar
• Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O, La Du BN. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase /arylesterase. Proc Natl Acad Sci USA 1995; 92:7187–7191.
   PubMed Web of Science ®Google Scholar
• Mehdi MM, Rizvi SI. Human plasma paraoxonase 1 (PON1) arylesterase activity during aging: correlation with susceptibility of LDL oxidation. Arch Med Res 2012; 43:438–443.
   PubMed Web of Science ®Google Scholar